当前位置: X-MOL 学术Biomol. Biomed. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Development and validation a novel preoperative comprehensive prognostic score based on inflammatory and nutritional score, coagulation indicator and tumor marker in esophageal squamous cell carcinoma.
Biomolecules and Biomedicine ( IF 3.4 ) Pub Date : 2021-10-19 , DOI: 10.17305/bjbms.2021.6350
Jifeng Feng 1 , Liang Wang 1 , Xun Yang 1 , Qixun Chen 1
Affiliation  

We herein propose a novel integrative score based on inflammatory and nutritional score, coagulation indicator and tumor marker, named comprehensive prognostic score (CPS), to predict postoperative survival in resectable esophageal squamous cell carcinoma (ESCC). We also aimed to establish and validate a nomogram based on CPS and other clinical features for individual survival prediction. A total of 490 resectable ESCC patients were randomly divided into either a training or validation cohort at a ratio of 7:3 for retrospective analysis. The CPS, based on squamous cell carcinoma antigen (SCCA), C-reactive protein to albumin ratio (CAR), neutrophil to lymphocyte ratio (NLR), and fibrinogen (FIB), was divided into two models to verify its prognostic value. The predictive model of CPS-based nomogram was established and validated in two cohorts. Patients with CPS low group in model 1 had better 5-year cancer-specific survival (CSS) than those in CPS high group (50.7% vs. 17.8%, P<0.001). For model 2, the 5-year CSS for CPS 0, 1 and 2 were 75.0%, 38.9% and 13.3%, respectively (P<0.001). CPS was confirmed as an independent prognostic score in both models. The CPS-based nomogram can accurately and effectively predict survival in resected ESCC. The CPS is a novel, simple, and effective predictor in resectable ESCC. Moreover, CPS has a potential independent prognostic value in predicting postoperative survival, which can accurately and effectively predict individual survival in resectable ESCC.

中文翻译:

基于炎症和营养评分、凝血指标和肿瘤标志物的食管鳞状细胞癌术前综合预后评分的开发和验证。

我们在此提出了一种基于炎症和营养评分、凝血指标和肿瘤标志物的新型综合评分,称为综合预后评分 (CPS),用于预测可切除食管鳞状细胞癌 (ESCC) 的术后存活率。我们还旨在建立和验证基于 CPS 和其他临床特征的列线图,用于个体生存预测。共有 490 名可切除的 ESCC 患者以 7:3 的比例随机分为训练或验证队列进行回顾性分析。基于鳞状细胞癌抗原 (SCCA)、C 反应蛋白与白蛋白比率 (CAR)、中性粒细胞与淋巴细胞比率 (NLR) 和纤维蛋白原 (FIB) 的 CPS 分为两个模型以验证其预后价值。基于 CPS 的列线图的预测模型在两个队列中建立和验证。模型 1 中 CPS 低组患者的 5 年癌症特异性生存率 (CSS) 优于 CPS 高组患者(50.7% 对 17.8%,P<0.001)。对于模型 2,CPS 0、1 和 2 的 5 年 CSS 分别为 75.0%、38.9% 和 13.3%(P<0.001)。CPS 在两种模型中都被确认为独立的预后评分。基于 CPS 的列线图可以准确有效地预测切除的 ESCC 的存活率。CPS 是一种新颖、简单且有效的可切除 ESCC 预测指标。此外,CPS 在预测术后生存率方面具有潜在的独立预后价值,可以准确有效地预测可切除 ESCC 的个体生存率。分别为 0%、38.9% 和 13.3% (P<0.001)。CPS 在两种模型中都被确认为独立的预后评分。基于 CPS 的列线图可以准确有效地预测切除的 ESCC 的存活率。CPS 是一种新颖、简单且有效的可切除 ESCC 预测指标。此外,CPS 在预测术后生存率方面具有潜在的独立预后价值,可以准确有效地预测可切除 ESCC 的个体生存率。分别为 0%、38.9% 和 13.3% (P<0.001)。CPS 在两种模型中都被确认为独立的预后评分。基于 CPS 的列线图可以准确有效地预测切除的 ESCC 的存活率。CPS 是一种新颖、简单且有效的可切除 ESCC 预测指标。此外,CPS 在预测术后生存率方面具有潜在的独立预后价值,可以准确有效地预测可切除 ESCC 的个体生存率。
更新日期:2021-10-19
down
wechat
bug